Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216298 | 0.81 | HRH4 (0.43) | MAPK14 | |
| SCHEMBL214920 | 0.81 | MAPK14 (0.42) | KCNH2MAPK14 | |
| SCHEMBL216234 | 0.78 | IRAK4 (0.44) | — | |
| SCHEMBL2735336 | 0.78 | KCNH2 (0.42) | KCNH2RPS6KA2 | |
| SCHEMBL214506 | 0.74 | MAPK14 (0.34) | KCNH2MAPK14 | |
| Hydrochloric Acid SCHEMBL215304 | 0.73 | MAPK14 (0.34) | KCNH2MAPK14 | |
| SCHEMBL215040 | 0.73 | MEN1 (0.40) | — | |
| SCHEMBL215772 | 0.73 | AURKA (0.35) | KCNH2MAPK14 | |
| SCHEMBL214523 | 0.72 | MAPK14 (0.35) | KCNH2MAPK14 | |
| SCHEMBL213793 | 0.72 | RAB9A (0.43) | RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | KCNH2 2774/4885RPS6KA2 268/4885MAPK14 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.